MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) announced its earnings results on Thursday. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.12), Briefing.com reports. During the same quarter last year, the firm earned ($0.18) EPS.
MoonLake Immunotherapeutics Trading Up 2.2 %
Shares of MLTX stock traded up $1.11 during mid-day trading on Friday, reaching $51.78. The stock had a trading volume of 195,056 shares, compared to its average volume of 234,016. The business's fifty day moving average is $49.35 and its 200-day moving average is $45.41. MoonLake Immunotherapeutics has a 1-year low of $35.53 and a 1-year high of $64.98. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -56.90 and a beta of 1.28.
Analyst Upgrades and Downgrades
Several analysts recently issued reports on MLTX shares. Wolfe Research cut MoonLake Immunotherapeutics from an "outperform" rating to a "peer perform" rating in a research report on Monday, August 26th. Cantor Fitzgerald restated an "overweight" rating on shares of MoonLake Immunotherapeutics in a report on Monday, September 23rd. HC Wainwright restated a "buy" rating and set a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Friday. Wedbush restated an "outperform" rating and issued a $73.00 target price (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday. Finally, Needham & Company LLC restated a "buy" rating and set a $62.00 price objective on shares of MoonLake Immunotherapeutics in a report on Thursday, September 12th. Two equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, MoonLake Immunotherapeutics has an average rating of "Moderate Buy" and an average target price of $78.80.
Read Our Latest Report on MoonLake Immunotherapeutics
Insider Buying and Selling at MoonLake Immunotherapeutics
In other news, Director Simon Sturge sold 171,000 shares of the firm's stock in a transaction dated Friday, October 4th. The stock was sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the sale, the director now directly owns 171,980 shares in the company, valued at $9,238,765.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.02% of the stock is owned by corporate insiders.
About MoonLake Immunotherapeutics
(
Get Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Further Reading
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
